Lead preclinical program, DRX-184 (d-S-bupropion), granted new US patent with term to May 2044. BOSTON, April 23, 2025 /PRNewswire/ — DeuteRx, LLC, a biopharmaceutical company developing novel small molecule therapeutics, today announced that Chair, President, and CEO Sheila DeWitt, PhD,…
